GREENWICH, Conn.--(BUSINESS WIRE)--April 19, 2006--Aptuit, Inc. announced today that Dr. Michael J. Butler has been appointed President, Scientific Operations of its rapidly growing drug development services offering. Dr. Butler brings to Aptuit 20 years of experience in pharmaceutical drug development, most recently as Group Vice President, Early Clinical and Bioanalytical and Senior Vice President, Marketing and Business Development at MDS Pharma Services where he led multi-site operations as well as oversaw strategic alignment of the largest segments of the company's $378M global operations. Dr. Butler will assume responsibility for all of Aptuit's scientific operations which span Active Pharmaceutical Ingredient Development (API), Preclinical Technologies, Analytics, and Pharmaceutics, which together have a complement of over 875 scientists and technical staff in Kansas City, Missouri and Edinburgh, Scotland.
